Panacea Biotec is currently trading at Rs. 120.85, up by 5.95 points or 5.18% from its previous closing of Rs. 114.90 on the BSE.
The scrip opened at Rs. 114.80 and has touched a high and low of Rs. 127.00 and Rs. 110.10 respectively. So far 31,000 shares were traded on the counter.
The BSE group 'B' stock of face value Rs. 1 has touched a 52 week high of Rs. 155.00 on 25-Jul-2016 and a 52 week low of Rs. 83.90 on 12-Feb-2016.
Last one week high and low of the scrip stood at Rs. 127.00 and Rs. 110.10 respectively. The current market cap of the company is Rs. 740.22 crore.
The promoters holding in the company stood at 74.60%, while Institutions and Non-Institutions held 0.13% and 25.27% respectively.
Panacea Biotec, one of India’s leading research based health management company, has launched Tetravalent Vaccine 'Easyfour-TT' for active primary immunization and booster dose against diphtheria, tetanus and pertussis (DTP) and Haemophilus Influenza Type B (Hib). Easyfour-TT (DTwP-Hib), world’s first fully liquid Tetravalent vaccine launch in India will protect infant from Diptheria, Tetanus, Whopping Cough, Hib-Meningitis.
Easyfour-TT is a sterile and uniform suspension, manufactured using CDAP technology with WHO Pre-Qualified antigens which ensures good quality, high immunogenicity and less reactogenicity. Being fully liquid, product requires no reconstitution, therefore saves time and minimizes chance of error. Easyfour-TT comes with a legacy of being a tried and tested brand in pediatric clinical trials ensuring good ethnic response with a better reactogenicity profile.
Panacea Biotec is the largest biotechnology company as well as among the top 50 pharmaceutical companies of India. The company has product portfolio that’s caters therapeutics areas like pain management, diabetes and cardiovascular management, renal disease management, osteoporosis management, anti-tubercular, gastro-intestinal.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1777.65 |
| Dr. Reddys Lab | 1194.55 |
| Cipla | 1465.65 |
| Lupin | 2043.30 |
| Zydus Lifesciences | 944.25 |
| View more.. | |
MoneyWorks4Me rating and ranking of funds for SIP is available to subscribers only. Moneyworks4Me is not a rating and ranking agency, however it is required that users have a way of selecting funds and building a Portfolio. The method used by it are described below to enable users to understand the logic behind the rating and ranking Subscriber will find more details on this in the various content made available from time to time. In case you need more please write to besafe@moneyworks4Me.com
MoneyWorks4Me rates and ranks mutual funds based on the following data-driven system:
Funds ranking in screeners: Performance Consistency and Quality are two parameters used for ranking funds for SIP. The ranking as follows GG, GO, GR, OG, OO, OR, RG, RO and RR.
With the same color-coded funds, the one with the higher Average 3-year rolling returns (over 5 to 10 years), the number that appears in the Performance tag, ranks higher.
Here is the summary:
The third tag Upside Potential is not relevant for SIP. It is relevant for lumpsum investments in Mutual Funds.
Make an informed decision for Stocks
Invest using an intelligent system with powerful data-driven tools that help you identify opportunities and make informed buy-hold-sell decisions
Buy quality Stocks when they are available at reasonable prices and supported by an upward price trend and Sell when they are Overvalued using the Decizen Rating System. Covers 3500+ stocks
Claim your FREE 15-day access to the most practical investing handbook.
Hurry, limited to the first 10 users today!
FREE Become a savvy and confident
stock investor.
Hurry, limited to the first 10 users today!
Download APP
